Organization | Institut d'Hématologie et d'Oncologie Pédiatrique, Lyon

Institut d'Hématologie et d'Oncologie Pédiatrique, Lyon Report issue

Academic/Hospital Phase 2 Phase 3

Organization Overview

First Clinical Trial

2011

NCT01314300

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2015

Timeline

NOW

Now

Alternative names

IHOP | IHOP, Lyon

Active Ingredients

Drugs in Phase 3 Trials (7)

carboplatin (paraplatin) (1 trial)

cisplatin (platinol) (1 trial)

cyclophosphamide (cytoxan) (1 trial)

etoposide (vepesid) (1 trial)

naltrexone (revia) (1 trial)

valproic acid (depakene) (1 trial)

vincristine (oncovin) (1 trial)

Drugs in Phase 2 Trials (1)

lidocaine (xylocaine) (1 trial)

Drugs in Other Trials (1)

asparaginase (elspar) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Ependymoma (Phase 3)

Neuralgia (Phase 2)

Overview

Highest Phase: Phase 3
# of Trials: 3
# of Trial APIs: 9